Managing Subacute Bowel Obstruction in Oncology Pa
Shared on November 18, 2026
Palliative Care Case Workshop: Bowel Obstruction and Medication Decisions
Overview
A clinical teaching session on interpreting a bowel obstruction case and selecting or adjusting medicines for a patient with advanced cancer. Key topics include obstruction type, antiemetic choice, renal impairment, opioid conversion, and identifying the likely cause of dry mouth.
Key Concepts
- “Complete” and “subacute” bowel obstruction are contradictory descriptions in this context: subacute indicates a partial obstruction, while complete means total blockage. Check clinical documentation for internal inconsistencies.
- A tumour physically compressing the bowel causes a mechanical obstruction. A functional obstruction results from impaired gut movement, such as from nerve dysfunction.
- Medication choices must account for the obstruction, renal function, route of administration, and side-effect profile.
- Opioid conversion guidance varies. Apply the relevant guideline and consider patient-specific factors rather than treating dose conversions as exact.
Detailed Notes
Bowel obstruction and antiemetics
- For the case, the obstruction was treated as complete and mechanical, caused by the cancer mass compressing the bowel.
- Suitable antiemetic options identified were cyclizine or haloperidol; in this case, treatment was later changed to haloperidol, which was easier to administer via a syringe driver.
- Avoid metoclopramide and domperidone because their prokinetic effects can increase gut motility against an obstruction.
- Ondansetron is not prokinetic, but its constipating effect makes it undesirable in this situation.
- Antiemetics may be administered by subcutaneous infusion when the patient is nil by mouth.
Renal impairment
- The calculated creatinine clearance was 24.5 mL/min.
- The creatinine increase was attributed to likely tumour compression of a ureter. Obstructed urine flow can cause urine to back up into the kidney, leading to swelling and kidney damage.
- Cyclizine or haloperidol may still be used with renal impairment, but the guidance is to start at a low dose and titrate cautiously.
Opioid conversion
- The patient’s oral modified-release morphine dose was 50 mg twice daily, or 100 mg in 24 hours.
- In the workshop’s conversion method, divide the 24-hour morphine dose by three to estimate subcutaneous oxycodone: 100 ÷ 3 = 33.3 mg.
- After applying the case-specific renal adjustment of 75%, the suggested syringe-driver dose was approximately 25 mg of subcutaneous oxycodone over 24 hours.
The session contrasted this method with general BNF guidance, which gives a higher direct equivalent of approximately 50 mg oxycodone for 100 mg morphine, followed by a 25–50% dose reduction when switching opioids. The palliative care guideline incorporates a dose reduction into its conversion approach. In practice, follow the applicable guidance and account for factors such as age, frailty, pain control, opioid tolerance, and prior tolerability.
Dry mouth
- Haloperidol was considered the most likely cause of the patient’s new dry mouth because it is more strongly associated with this effect.
- Oxycodone could contribute, but morphine and oxycodone generally have similar opioid side-effect profiles; the change in opioid alone was considered a less likely explanation.
Next case
The workshop then moved to a lung cancer case. Participants were advised that the answer to its first question was not heart failure. A later question required both a new patch dose and the accompanying as-needed (PRN) dose.
More public notes
Browse all public notesAntiemetic Protocols and Palliative Care Workshop
November 18, 2026
Managing SVC Obstruction in Small Cell Lung Cancer
November 18, 2026
The Russian Revolution
November 18, 2026
Criação de Processos - iCEV
November 9, 2026
Het oog: structuur, functies en reflexen
November 1, 2026
New note
October 26, 2026